|
|
|
|
Product news (13 March 2010)
SPCs for medicines are available online Prescription products Intanza (split virion, inactivated influenza vaccine) suspension for injection in pre-filled syringe, 9g and 15g, is now available from Sanofi Pasteur MSD.Net price: 1 x 9g, 9.05 1 x 15g, 9.05...
|
|
|
Ondansetron 4 mg and 8 mg Film-Coated Tablets - PL 04416/0875-8; UK/H/1338-9/001-2/DC
_ Ondansetron 4 mg and 8 mg Film-Coated Tablets - PL 04416/0875-8; UK/H/1338-9/001-2/DC.
|
|
|
Vomiting Therapy: Recent findings from University Hospital highlight research in vomiting therapy
Today's Medical & Research News Vomiting Therapy Recent findings from University Hospital highlight research in vomiting therapy March 3rd, 2010 Printer-Friendly Version City:Amman Country:Jordan Vomiting Therapy Analgesia Anesthesia Cholecystectomy...
|
|
|
Aprepitant vs. Multimodal Prophylaxis in the Prevention of Nausea and Vomiting following Extended-Release Epidural Morphine
Background: Extended-release epidural morphine (EREM) is an effective option for postoperative analgesia following major orthopedic surgery; however, postoperative nausea/vomiting (PONV) is a recognized limitation.The incidence of PONV following prophylactic...
|
|
|
Ondansetron: A meta-analysis on its efficacy to prevent postoperative nausea and vomiting after craniotomy in adults and children
Frost F et al.Peroperative intravenous dose of ondansetron 4 mg in neurosurgery in adults is required to prevent PONV during the first postoperative 24 hours. Ondansetron: A meta-analysis on its efficacy to prevent postoperative nausea and...
|
|
|
Avoid diphenhydramine, ranitidine after perforated appendicitis: study
NEW YORK (Reuters Health) - Giving the antihistamines ranitidine or diphenhydramine to patients with perforated appendicitis dramatically increases their risk of an intra-abdominal abscess, according to a new study.Giving one or the other agent doubled the...
|
|
|
Boston Scientific to Cut up to 1,300 Employees: Biotech's Weekly Mishaps Report
Medical device giant Boston Scientific (BSX) said it would eliminate as many as 1,300 jobs or 10 percent of its workforce as part of a series of restructuring initiatives and management changes it says will drive profitable growth for the company.As part of...
|
|
|
Ondansetron Ineffective for Chronic Fatigue Syndrome
In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.To find out how to adjust your browser settings to accept cookies, please click here. Medscape uses cookies to customize the site based on the information...
|
|
|
Ondansetron Ineffective for Chronic Fatigue Syndrome
In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.To find out how to adjust your browser settings to accept cookies, please click here. Medscape uses cookies to customize the site based on the information...
|
|
|
Boston Scientific to Cut up to 1,300 Employees: Biotech's Weekly Mishaps Report
Medical device giant Boston Scientific (BSX) said it would eliminate as many as 1,300 jobs or 10 percent of its workforce as part of a series of restructuring initiatives and management changes it says will drive profitable growth for the company.As part of...
|
|
|
Strativa gets FDA Complere Response letter for Zuplenz NDA
- Strativa Pharmaceuticals, the proprietary products division of a wholly-owned subsidiary of Par Pharmaceutical Companies Inc (NYSE: PRX), said last Friday that the US Food and Drug Administration (FDA) has issued a Complete Response letter regarding the New...
|
|
|
Oral strip ondansetron held up at FDA
A novel formulation of ondansetron has seen its marketing application delayed at the US Food and Drug Administration (FDA) because the agency has been unable to carry out an inspection of overseas sites involved in testing and developing the product.
|
|
|
FDA Issues Complete Response Letter Regarding Strativa Pharmaceutical's NDA for Zuplenz Oral Soluble Film
Strativa Pharmaceuticals has announced that the FDA issued a complete response letter regarding the new drug application (NDA) for Zuplenz (ondansetron) oral soluble film for the prevention of nausea and vomiting associated with highly- and moderately...
|
|
|
FDA issues complete response letter for Zuplenz
WOODCLIFF LAKE,N.J.(Feb. 8) The Food and Drug Administration has declined to approve a drug made by Strativa Pharmaceuticals for preventing sickness resulting from some cancer treatments, Strativa said Friday. The FDA issued a complete response letter...
|
|
|
Strativa Pharmaceuticals Provides An Update On Zuplenz (Ondansetron) Oral Soluble Film
FDA has not completed its inspection of the bioequivalence study sites due to an agency-wide restriction on foreign travel to India WOODCLIFF LAKE, N.J., Feb.5 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals announced today that the U.S. Food and Drug...
|
|
|
Incomplete plant inspections prevent Zuplenz approval
Unable to complete necessary plant inspections in India, Strativa Pharmaceuticals and Par Pharmaceuticals said today that the FDA couldn't approve the NDA for Zuplenz (ondansetron).The drug is an oral soluble film that prevents nausea and vomiting...
|
|
|
Par Pharma (PRX) Subsidiary Strativa Receives Response Letter from U.S. FDA for Zuplenz
Strativa Pharmaceuticals, a Par Pharmaceutical (NYSE: PRX) subsidiary, announced today that the U.S.Food and Drug Administration (FDA) issued a complete response letter regarding the new drug application (NDA) for Zuplenz (ondansetron) oral soluble...
|
|
|
Strativa Pharmaceuticals Provides An Update On Zuplenz(R) (Ondansetron) Oral Soluble Film
FDA has not completed its inspection of the bioequivalence study sites due to an agency-wide restriction on foreign travel to India PR Newswire WOODCLIFF LAKE, N.J., Feb.5 WOODCLIFF LAKE, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals...
|
|
|
Strativa Pharmaceuticals Provides An Update On Zuplenz(R) (Ondansetron) Oral Soluble Film
FDA has not completed its inspection of the bioequivalence study sites due to an agency-wide restriction on foreign travel to India PR Newswire WOODCLIFF LAKE, N.J., Feb.5 WOODCLIFF LAKE, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals...
|
|
|
Strativa Pharmaceuticals Provides An Update On Zuplenz(R) (Ondansetron) Oral Soluble Film
FDA has not completed its inspection of the bioequivalence study sites due to an agency-wide restriction on foreign travel to India PR Newswire WOODCLIFF LAKE, N.J., Feb.5 WOODCLIFF LAKE, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals...
|
|
|
Strativa Pharmaceuticals Provides An Update On Zuplenz(R) (Ondansetron) Oral Soluble Film
FDA has not completed its inspection of the bioequivalence study sites due to an agency-wide restriction on foreign travel to India PR Newswire WOODCLIFF LAKE, N.J., Feb.5 WOODCLIFF LAKE, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals...
|
|
|
Strativa Pharmaceuticals Provides An Update On Zuplenz(R) (Ondansetron) Oral Soluble Film
FDA has not completed its inspection of the bioequivalence study sites due to an agency-wide restriction on foreign travel to India PR Newswire WOODCLIFF LAKE, N.J., Feb.5 WOODCLIFF LAKE, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals...
|
|
|
Strativa Pharmaceuticals Provides An Update On Zuplenz(R) (Ondansetron) Oral Soluble Film
FDA has not completed its inspection of the bioequivalence study sites due to an agency-wide restriction on foreign travel to India PR Newswire WOODCLIFF LAKE, N.J., Feb.5 WOODCLIFF LAKE, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals...
|
|
|
Strativa Pharmaceuticals Provides An Update On Zuplenz(R) (Ondansetron) Oral Soluble Film
FDA has not completed its inspection of the bioequivalence study sites due to an agency-wide restriction on foreign travel to India PR Newswire WOODCLIFF LAKE, N.J., Feb.5 WOODCLIFF LAKE, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals...
|
|
|
Strativa Pharmaceuticals Provides An Update On Zuplenz(R) (Ondansetron) Oral Soluble Film
FDA has not completed its inspection of the bioequivalence study sites due to an agency-wide restriction on foreign travel to India PR Newswire WOODCLIFF LAKE, N.J., Feb.5 WOODCLIFF LAKE, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals...
|
